BioLineRx Presents Pre-Clinical Data Demonstrating That BL-1021 Is Safe And Effective In Treating Neuropathic Pain

BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced the presentation of data from pre-clinical trials of BL-1021 at the Isranalytica meeting 2008 held in Tel Aviv, Israel, on January 22-23, 2008. Recent pre-clinical trials demonstrated that BL-1021 was safe and effective in pre-clinical testing for the treatment of neuropathic pain.

More: continued here

Filed under: Pain / Anesthetics on February 7th, 2008